897652-03-8

Basic information

• Product Name: 1-(4-CHLOROPHENYL)PIPERIDIN-4-AMINE
• Synonyms: 1-(4-CHLOROPHENYL)PIPERIDIN-4-AMINE
• CAS NO: 897652-03-8
• Molecular Formula: C11H15ClN2
• Molecular Weight: 210.7032
• Mol File: 897652-03-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 341.3±37.0 °C(Predicted)
• Appearance: /
• Density: 1.162±0.06 g/cm3(Predicted)
• PKA: 10.04±0.20(Predicted)
• CAS DataBase Reference: 1-(4-CHLOROPHENYL)PIPERIDIN-4-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-CHLOROPHENYL)PIPERIDIN-4-AMINE(897652-03-8)
• EPA Substance Registry System: 1-(4-CHLOROPHENYL)PIPERIDIN-4-AMINE(897652-03-8)

Safety Data

• Hazardous Substances Data: 897652-03-8(Hazardous Substances Data)

Usage

Chemical class

Piperidine derivatives

Type of compound

Synthetic cannabinoid receptor agonist

Active ingredient

Identified in some synthetic cannabis products

Psychoactive effects

Central nervous system

Regulatory control

Subject to control in some countries due to potential for abuse and harmful health effects

Legal and regulatory scrutiny

Has been the subject of legal and regulatory scrutiny due to its psychoactive properties and potential risks.

Upstream product

• 73874-95-0 (piperidin-4-yl)carbamic acid tert-butyl ester 
• 1679-18-1 4-Chlorophenylboronic acid 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with the enzyme glycolate oxidase (GO). Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.